Novo Nordisk Rises 25% on Oral GLP-1 Optimism, but DeepValue Report Flags Structural Pricing Risks

What happened

Novo Nordisk shares surged 25% from multi-year lows on optimism around oral Ozempic and Wegovy pill launches, FDA approvals, and telehealth collaborations, with the company even modestly raising sales guidance. However, the latest DeepValue Master Report maintains a WAIT rating at $44.9, emphasizing that the stock's low multiples (12.4x P/E, 8.8x EV/EBITDA) already discount sustained U.S. net-price compression and ongoing share loss to Eli Lilly. The report warns that the Q1 2026 reported revenue will be distorted by a one-time $4.2B 340B recognition, masking underlying pricing and volume trends. While the article highlights volume defense via new channels, the filing confirms that Novo lost weekly prescription leadership in both Wegovy and Ozempic during 2025 and faces unprecedented pricing pressure. The bullish thesis hinges on whether telehealth distribution and the Wegovy Pill can stabilize volumes without further price cuts below the current $249–$399/month self-pay menu.

Implication

Novo's low valuation offers a margin of safety if price concessions remain bounded and volume defense materializes via oral GLP-1 and telehealth. However, the next two quarters must show that share loss has stabilized and price reset is contained; otherwise, the stock could re-test lows near $36.

Thesis delta

The bullish narrative in the article—that 'restructuring efforts are beginning to bear fruit'—is partially contradicted by the DeepValue report's evidence of structural pricing pressure and lost market share. The delta is that positive sentiment from product launches and guidance hikes does not yet offset the reality of a deteriorating U.S. pricing regime and competitive dynamics. The thesis shifts from a potential turnaround to a 'prove it' wait, as the reported sales boost is accounting-driven and sustainable volume defense is unconfirmed.